Surmodics shares are trading higher after the company announced it received FDA approval for the SurVeil drug-coated balloon.
Portfolio Pulse from Benzinga Newsdesk
Surmodics has received FDA approval for its SurVeil drug-coated balloon, leading to a surge in its share prices.
June 20, 2023 | 3:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Surmodics' FDA approval for SurVeil drug-coated balloon has led to an increase in its share prices.
The FDA approval for Surmodics' SurVeil drug-coated balloon is a significant milestone for the company, as it allows them to market and sell the product. This positive news has led to an increase in the company's share prices, as investors anticipate potential growth in revenues and market share.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100